Viewing data from:

IMIQUIMOD

ANDA

IMIQUIMOD | A078548 | FOUGERA PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: ZYCLARA(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Imiquimod (2023)

Total Spending

$8.6M

Total Claims

186,313

Beneficiaries

124,101

Avg Cost/Unit

$2.69

Spending Trend

$10.2M(2019)→$9.5M(2020)→$8.3M(2021)→$8.3M(2022)→$8.6M(2023)

YoY Change:-3.6%

5yr CAGR:-7.6%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain10 active DMFs3 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

TARO PHARMACEUTICAL INDUSTRIES LTDIMIQUIMOD USP

DMF 180312005

TAPI NL BVIMIQUIMOD

DMF 187822005

WAVELENGTH ENTERPRISES LTDIMIQUIMOD

DMF 190092005

TEVA PHARMACEUTICAL INDUSTRIES LTDIMIQUIMOD

DMF 195072006

ALIVUS LIFE SCIENCES LTDIMIQUIMOD USP

DMF 197352006

INTERQUIM SAIMIQUIMOD

DMF 202472007

USV PRIVATE LTDIMIQUIMOD USP

DMF 203532007

ACTAVIS GROUP PTC EHFIMIQUIMOD USP [NON-STERILE DRUG SUBSTANCE]

DMF 216102008

SOLARA ACTIVE PHARMA SCIENCES LTDIMIQUIMOD

DMF 221592008

WANBURY LTDIMIQUIMOD

DMF 320172017

TAI HENG INDUSTRY CO LTDInactiveIMIQUIMOD

DMF 202562007

AMINO CHEMICALS LTDInactiveIMIQUIMOD

DMF 207362007

CIPLA LTDInactiveIMIQUIMOD

DMF 219272008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Mar 3, 2010	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 5%

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Feb 25, 2010

No patent or exclusivity listings for this strength.